| 规格或纯度 | Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated |
|---|---|
| 英文名称 | Obinutuzumab (anti-CD20) |
| 别名 | Gazyva; GA101; Gazyvaro; Afutuzumab; 奥滨尤妥珠单抗; 阿托珠单抗; APY antibody; ATOPY antibody; B lymphocyte antigen CD20 antibody; B Lymphocyte Cell Surface Antigen B1 antibody; B-lymphocyte antigen CD20 antibody; B-lymphocyte cell-surface antigen B1 antibody; B-lymp |
| 英文别名 | Gazyva; GA101; Gazyvaro; Afutuzumab; APY antibody; ATOPY antibody; B lymphocyte antigen CD20 antibody; B Lymphocyte Cell Surface Antigen B1 antibody; B-lymphocyte antigen CD20 antibody; B-lymphocyte cell-surface antigen B1 antibody; B-lymphocyte surface a |
| 应用 | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| 来源 | CHO supernatant |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 产品介绍 |
Obinutuzumab是新型糖工程化 II 型 CD20 人源化 IgG1 单克隆抗体，用于非霍奇金淋巴瘤的研究。 Obinutuzumab is a novel glyca-engineered type II CD20 humanized IgG1 monoclonal antibody for non-Hodgkin lymphoma. |
| IMGT/mAb-DB | 238 |
|---|---|
| Wikipedia | Obinutuzumab |
| PubChem SID | 178103523 |
| PEP | obinutuzumab |
| 稳定性与储存 | Store at -80℃ for 2 years. Avoid repeated freeze/thaw cycles. |
|---|
| Target ID | 2628 | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 名称 | CD20 (membrane-spanning 4-domains, subfamily A, member 1) | ||||||||||||||||||||||||
| 缩写名 | SHP2 | ||||||||||||||||||||||||
| 家族 | CD molecules | ||||||||||||||||||||||||
| 别名 | thromboxane A2 / prostaglandin H2 | ||||||||||||||||||||||||
| 基因和蛋白信息 |
|
||||||||||||||||||||||||
| Entrez Gene | 931 (Hs) , 12482 (Mm) , 309217 (Rn) | ||||||||||||||||||||||||
| UniProtKB | P11836 (Hs) , P19437 (Mm) | ||||||||||||||||||||||||
| Ensembl Gene | ENSG00000156738 (Hs) , ENSMUSG00000024673 (Mm) , ENSRNOG00000020945 (Rn) | ||||||||||||||||||||||||
| RefSeq Nucleotide | NM_001107578 (Rn) , NM_007641 (Mm) , NM_152866 (Hs) | ||||||||||||||||||||||||
| RefSeq Protein | NP_001101048 (Rn) , NP_031667 (Mm) , NP_690605 (Hs) | ||||||||||||||||||||||||
| OMIM | 112210 (Hs) | ||||||||||||||||||||||||
| Orphanet | 235193 (Hs) | ||||||||||||||||||||||||
| Protein GI | 23110989 (Hs) , 6671710 (Mm) , 157817414 (Rn) | ||||||||||||||||||||||||
| DrugBank Target | P11836 (Hs) | ||||||||||||||||||||||||
| ChEMBL Target | CHEMBL2058 (Hs) |
| Ligand ID | 6941 |
|---|---|
| 名称 | obinutuzumab |
| 别名 | Gazyva® |
| 类别 | Antibody |
| 学名 | 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide |
| 生物活性评价 |
In vitro, obinutuzumab induces cell death and antibody-dependent cell-mediated cytotoxicity (ADCC) more effectively than the original type I anti-CD20 antibodies However, we have been unable to find affinity data for this antibody from any open access source. |
| 评价 |
Obinutuzumab is a third-generation, humanized and glyco-engineered anti-CD20 IgG1 mAb. Prior to 2009 obinutuzumab was known as afutuzumab. Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
| 单字母多肽序列 | |
| 三字母多肽序列 | |
| 翻译后修饰 | |
| 化学修饰 | |
| 临床描述 |
This Phase II study will compare the efficacy and safety of obinutuzumab plus mycophenolate mofetil (MMF)/mycophenolic acid (MPA) with placebo plus MMF/MPA in participants with proliferative LN. |
| 来源公司 |
Hoffmann-La Roche |
| 1. Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S et al.. (2013) Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.. Mol Cancer Ther, 12 (10): (2031-42). [PMID:23873847] |
Obinutuzumab (anti-CD20) (O412011) - Flow Cytometry
Flow Cytometry analysis of Raji cells labelling CD20 (red) with Obinutuzumab (anti-CD20) (O412011). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Obinutuzumab (anti-CD20) (O412011) - SEC
The purity of Obinutuzumab (anti-CD20) (O412011) is more than 95% verified by HPLC.
首页
400-620-6333
危险品化学品经营许可证（带存储）